The European Medicines Agency is considering a more “tailored” approach to the assessment of new biosimilar medicines, with a focus on whether to waive the requirement for comparative efficacy studies when the biosimilar shows a high degree of similarity to the reference drug.
At present, the comparability exercise for biosimilars in the EU comprises the evaluation of quality data, in vitro and in...